What Happened to Google Health?

Monday, 01 August 2011 07:25 Written by Mark Klapper

Google’s recent announcement that it was shutting down Google Health has left people wondering about the future of personal health records (PHRs) and the degree of interest among wary consumers in managing their health on the level that a service like Google Health would allow. Sorting through Google’s announcement, as well as several blog posts and articles, it seems that Google’s expectations for the service simply did not align with the still-emerging interest in a service that was not as well-defined as it needed to be to succeed.

PHRs are a niche product. According to Google, "There has been adoption among certain groups of users like tech-savvy patients and their caregivers, and more recently fitness and wellness enthusiasts. But we haven’t found a way to translate that limited usage into widespread adoption in the daily health routines of millions of people."

Google has other priorities. Google is a large public company. Good or bad, Wall Street backing brings high visibility and even higher expectations for every venture the company launches. Google has big plans for social media with Google +. Smaller Google-owned brands like Picasa and Blogger will be phased out as these platforms are integrated under the Google+ umbrella. Google Health doesn’t fit into these plans.

Consumers interested in PHRs need receptive healthcare providers. When a new Rx product is launched, physicians are hesitant to prescribe it until they have developed a level of comfort with the benefits and any potential risks. The same holds true for PHRs. HCPs are adapting to growing cost and access pressures and have not had much exposure or experience with PHRs. Without the support of a physician, consumers are unlikely to adopt PHRs.

PHRs are competing for attention and resources with electronic health records (EHRs). The electronic health record (EHR) is a longitudinal record of patient information that is designed to automate and streamline the workflow for everyone involved in the delivery of healthcare. While PHRs are a very logical extension of this platform, the adoption and integration of EHRs into practice is the 800-pound gorilla in the room. Once HCPs are comfortable with EHRs, the personal platform will take off. Look for more on EHRs in an upcoming blog post.

Physician reimbursement is based on face-to-face visits. In addition to a rapidly changing environment, doctors are likely recognizing that their compensation is often based only on office visits. While many acknowledge that over half of the time they spend on interactions does not need to be person, the real potential of PHRs will not be realized until there is an appropriate reimbursement model.

MBlog - Patients and Health Care Providers

Greetings from Eye for Pharma

Friday, 18 June 2010 10:32 Written by Mike Kalfus

Greetings from the Eye for Pharma “Patient Adherence” conference in beautiful Zurich, Switzerland. This conference focused on many key issues related to pharma marketing. Following are some highlights related to HCP and patient compliance.

Our first speaker was Przemyslaw Kardas from Medical University of Lodz. He discussed the differences HCP's and patients look at compliance.

Here were a few of his key points:

Lack of trust in their HCP's is directly related to lower adherence in patients
Working on project to provide evidenced-based information for policy makers in the EU

Some of the things he stated struck me as funny and never occurred to me until I heard him say…it was scary to think I was one of those people ‘getting older and more likely to develop a chronic condition’ but wondered if I was as compliant as I think I am.

Compliance and Adherence in HIV Treatment

Another speaker today was Marie-Pierre de Bethune from Scientific Affairs in J&J. She spoke on compliance and adherence in HIV treatment the R&D perspective at the conference this week:

Tags:

eye for pharma

MBlog - Conferences and Workshops

Taking Care of Caregivers

Wednesday, 16 June 2010 09:55 Written by Mike Kalfus

Rebecca Joslin at Global brand manager at Novartis gave a very good presentation on Caregivers who have family members with Alzheimer’s at the conference today in Zurich. It was very insightful and delivered well. An added bonus: I could actually read the slides-compared to many of the other decks which were very difficult to see/read on screen.

She stressed:

Caregivers don’t really know much about the drugs they are dispensing to their loved ones
Pharma should segment caregivers as they do other stakeholders
Caregivers are looking for free time and need support
Provide tailored pathway for the caregiver

Tags:

patients

MBlog - Patients and Health Care Providers

Beyond Direct to Consumer

Wednesday, 03 March 2010 07:25 Written by Mike Kalfus

Going beyond DTC, we see a future in applying consumer measurement tools to physician marketing. Non-personal promotion is the fastest-growing area in pharma. Some companies are beginning to delve into the area, but are looking at things more tactically than strategically.

Measurement is ground zero in the age of accountability—no matter if you are targeting consumers or physicians.

Margins are being cut and the need for more fine-tuning of the marketing mix is critical. You must have the ability to understand the key business drivers for the brand on both a physician and consumer marketing spend level.

Even though DTC is not practiced outside the US like it is here, there are some brands that effectively utilize direct-to-patient communications. Global direct-to-patient communications is the most challenging to measure. There is no patient longitudinal data, many countries have different waiting times to see a specialist and the list goes on.

Tags:

patients

MBlog - Patients and Health Care Providers

European Union Regulations

Wednesday, 01 August 2007 07:25 Written by Mike Kalfus

EU regulations on personal privacy are strict, and almost all European countries have added their own particular nuances. Despite this, there are many things that pharma marketers can do to communicate with their patients in the EU, but, to date, very few are doing much of anything.

Yes, the regulations are tight and there are big penalties if you cross the line. Because of that fact, many marketers seem to shy away from attempting to get closer to their patients; they shouldn’t, because that is doing both their company and their patients a disservice.

Many studies show that getting closer to your customer or patient always pays dividends. According to Deloitte and Touche, “Attracting a new customer is five times more expensive than retaining a current one, and retaining an additional 2% of customers annually can reduce operating expenses by 10%.” For consumers, it is in the measure of better health outcomes; for life science companies, it is measured by increased awareness and retention of patients who need better or more optimal treatment. These factors add up to increased patient compliance and a better return on any marketing investments you make (the ‘Holy Grail’ for life sciences marketers.) Some brands are doing it, but many others, even within the same organizations, don’t know anything about it. Sometimes marketers even collect the right information yet don’t do anything with it.

Tags: